Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK

R J Lomas, A Chandrasekar, C Macdonald-Wallis, S Kaye, S Rauz, F C Figueiredo

Research output: Contribution to journalArticlepeer-review

34 Downloads (Pure)


INTRODUCTION: Serum eye drops (SED) are an important treatment for patients with chronic and severe ocular surface disease (OSD). Despite a long history of use, there is a paucity of information on patient-reported outcomes, particularly comparing autologous SED (Auto-SED) and allogeneic SED (Allo-SED). National Health Service Blood and Transplant is the national provider of SED service for patients in the UK.

PURPOSE: To evaluate and compare patient-reported outcome measures (PROMs) in patients receiving Auto-SED and Allo-SED for severe OSD.

MATERIALS AND METHODS: PROMs were retrospectively collected from all new patients commencing treatment with Auto-SED and Allo-SED between January 2017 and September 2018, using the Ocular Surface Disease Index (OSDI) 12-item questionnaire. A linear mixed model was used to evaluate the change in OSDI scores between baseline and follow-up.

RESULTS: During the study period, 279 patients who received either Auto-SED (n = 71) or Allo-SED (n = 208) were included in the analysis. Baseline and follow-up OSDI scores were available for 161 of these (49 Auto-SED and 112 Allo-SED). There was a significant reduction in mean OSDI score for both Auto-SED (59.06-24.63, p < 0.001) and Allo-SED (64.21-34.37, p < 0.001). There was no significant difference between Auto-SED and Allo-SED patients in terms of the reduction in the OSDI score (p = 0.27).

CONCLUSION: Both Auto-SED and Allo-SED were associated with improvements in the quality of life of patients with chronic and severe OSD. Auto-SED and Allo-SED were equally effective in relieving the symptoms of OSD.

Original languageEnglish
Pages (from-to)3425-3432
Number of pages8
JournalEye (London, England)
Issue number12
Early online date16 Sept 2021
Publication statusPublished - Dec 2021

Bibliographical note

© 2021. Crown.


  • Graft vs Host Disease
  • Hematopoietic Stem Cell Transplantation/adverse effects
  • Humans
  • Ophthalmic Solutions
  • Patient Reported Outcome Measures
  • Quality of Life
  • Retrospective Studies
  • State Medicine
  • Transplantation, Autologous
  • Treatment Outcome
  • United Kingdom


Dive into the research topics of 'Patient-reported outcome measures for a large cohort of serum eye drops recipients in the UK'. Together they form a unique fingerprint.

Cite this